Zhaoke Ophthalmology Ltd. announced that its registration application for Atropine Sulfate Eye Drops (0.01% dose, product code: NVK002) for the treatment of myopia progression in children has been accepted for evaluation by Australia's Therapeutic Goods Administration $(TGA)$. The application, based on positive data from a Phase III clinical trial, has passed preliminary assessment and will proceed to formal evaluation. Atropine Sulfate Eye Drops (NVK002) is a novel topical ophthalmic solution with a proprietary, preservative-free formulation targeting children and adolescents aged 3 to 17 years. The company notes that approval for commercialization is not guaranteed at this stage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260113-11989239), on January 13, 2026, and is solely responsible for the information contained therein.